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ABSTRACT
Many new drug molecules suffer from poor bioavailability. The
majority of new drug candidates are poorly soluble which can
severely affect their bioavailability. For example, peptide drugs
have great potential in the treatment of illnesses but so far, their
commercial success has been restricted largely because of their
short duration of activity.
Mesoporous materials represent a nanotechnological solution
to the current problems in drug delivery. Improved dissolution
of poorly soluble drug or a sustained release of peptides can be
provided  by  loading  drugs  into  small  pores  which  are  only  a
few nanometers wide.
The successful development of a mesoporous drug carrier
involves both the production of the porous material and the
design of the appropriate surface chemistry. Furthermore, it is
essential to make a detailed characterization of the properties of
the carrier and the drug loaded inside the pores. Finally, the
delivery of the drugs in an active form needs to be assessed in
vivo and the safety of the material has to be confirmed.
The present work addresses all of the above mentioned
aspects of drug carrier development. More specifically, the
development of a method for controlling the pore size by
annealing of porous silicon is described. In addition, surface
stabilization by oxidation was studied to produce inert carrier
surfaces with a minimal effect  on the pore structure.  This work
also addressed the characterization of mesoporous materials by
development of a novel method for quantitative determination
of pore morphology of an ordered mesoporous silica material.
Furthermore, the physical state of a model drug, ibuprofen, in
the pores of porous silicon was studied. This study revealed the
effect of pore size and surface chemistry on the crystallinity of
the drug. Finally, delivery of a peptide from a porous silicon
carrier was studied with animal models. A sustained release of
peptide in an active form was achieved without any signs of
inflammatory reactions.
Universal Decimal Classification: 546.28, 620.3, 62-405.8, 661.8’065
National Library of Medicine Classification: QT 36.5, QT 37, QV 785
Medical Subject Headings: Biomedical and Dental Materials; Biological
Availability; Nanotechnology; Nanostructures; Porosity; Silicon; Drug
Carriers; Drug Delivery Systems; Surface Properties; Ibuprofen; Peptides;
Models, Animal
Yleinen suomalainen asiasanasto: materiaalitiede; nanotekniikka;
nanomateriaalit; huokoisuus; pii; lääkeaineet – annostelu; ibuprofeeni;
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1 Introduction
A large number of drugs encounter serious difficulties in their
delivery. In order for a drug to exert a therapeutic effect, it
needs to be delivered to the site of action at a sufficient
concentration and to be present for an adequate length of time.
Poorly soluble and peptide drugs are types of drugs that often
face difficulties meeting these demands.
The poor solubility of drugs is a serious and an increasing
problem in pharmaceutical industry. As many as 70 % of new
drug candidates suffer from poor solubility [1] and poor
solubility of drugs frequently leads to low bioavailability. In
order to increase the bioavailability, higher doses could be
administered but this strategy may cause other problems such
as toxicity, difficulties in formulation and high costs [2].
Several approaches have been developed to overcome poor
solubility [2]. Sometimes it is possible to chemically modify the
molecule or produce a salt form to obtain a more soluble form
[2]. However, these methods are not always successful or
desirable, and therefore physical methods are often used
instead. These physical methods include forming a metastable
polymorph, creating an amorphous form or reducing the
particle size down to the nanoparticle range [3]. These
approaches often suffer from poor physical stability [3]. It is also
possible to utilize excipients to improve dissolution properties.
Solid dispersions and co-crystals can be formed or the drug can
be complexed with cyclodextrins [3-5]. These formulations are
usually very specific for each drug molecule and thus
considerable formulation development has to be done for each
individual molecule [3-5]. In addition, the loading degrees
achieved with these methods are typically low and their
production can be complicated [2, 6].
Peptide/protein drugs also often encounter serious delivery
problems. Peptides and proteins are abundant in living
1
2organisms participating in various functions and diseases.
Therefore, peptide/protein drugs hold considerable promise for
the treatment of various illnesses. Despite their potential, only a
few peptide/protein drugs have reached the market, often
owing to serious difficulties in their delivery [7]. The two main
limitations in peptide/protein delivery are poor absorption
through non-invasive routes, and their short duration of activity
which is caused by the rapid renal clearance and enzymatic
degradation [7, 8]. Repeated injections are almost invariably
used to overcome these limitations, resulting in poor patient
compliance [7].
The most widely studied sustained release carriers of
peptides/proteins are various polymer-based formulations. In
addition, carriers such as liposomes and solid lipid
nanoparticles have been evaluated [9]. However, these
formulations have usually low loading degrees which make
them  an  unlikely  solution  for  drugs  which  need  to  be
administered at high doses [7, 9]. Furthermore, the polymer
formulations suffer from stability issues, difficulties in
manufacturing and their large particle size requiring painful
injections [7].
Mesoporous materials are potential drug carriers [10]. The
research in this field is rapidly increasing. According to the Web
of Science, over 1600 articles have been published in this field
since year 2000 with 60 % of the articles appearing during the
last 3 years.
Mesoporous materials consist of pores with diameters in the
range of 2 nm–50 nm, are typically highly porous and have large
specific surface areas. These structures have a high capacity to
absorb drug molecules into their pore structures achieving high
drug loading degrees.
The delivery of poorly soluble and peptide drugs from
mesoporous materials can resolve many of the problems
associated with these molecules. For poorly soluble drugs, an
enhanced release rate can be achieved by confining the drug
into mesopores. The improved release is a result of changes in
the physical state of loaded drugs and their large surface areas
[10]. Not only is the release rate enhanced but also the state of
the drug is efficiently stabilized. Furthermore, it has been shown
that this method can be extended to a wide variety of poorly
soluble drugs [11]. There is no need to tune the carrier according
to the properties of the drug, provided that one can ensure
chemical compatibility between drug and carrier. In addition,
loading of the carrier is uncomplicated, at least on a laboratory
scale, and can be performed at room temperature.
The use of mesoporous materials as carriers for
peptides/proteins is clearly an emerging and promising
application. One potential benefit of the carrier is a sustained
release resulting from attachment of molecules onto the surface
and diffusion limitations. In addition, the pore structure might
be able protect the molecules from enzymatic degradation prior
to release since the enzymes cannot gain access into the pores.
Successful preclinical development of a mesoporous carrier
involves the production of carrier with a suitable pore structure
and appropriate surface chemistry. In order to predict and
understand the behavior of the carrier, the properties such as
pore morphology have to be extensively characterized. It is
equally important to understand the properties of drugs in the
pores. Finally, the release and activity of the loaded drug have
to be evaluated as well as the safety of the material.
All of the above-mentioned aspects in development of
mesoporous carriers are discussed in the present work.  The
experimental work in the original publications begins with the
production of porous silicon, specifically with modifications to
the pore structure (I) and surface stabilization by oxidation (II).
A novel method was developed for the characterization of
mesoporous SBA-15; this method was capable of quantifying u-
shaped pores in the material (III). In addition, a study into the
characterization of crystalline ibuprofen in mesopores was
conducted (IV). Finally, it was shown that porous silicon could
be applied in sustained delivery of peptides in vivo (V).
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2 Literature review
Drug delivery by mesoporous materials including all related
topics is a very wide subject addressed by thousands of
scientific articles published during the last two decades.
Therefore, this review does not attempt to be an exhaustive
survey of the literature, but rather to introduce readers to the
subject and to provide a comprehensive account on the
phenomena and methods that are related to the topic. The
emphasis is on the mesoporous materials used in the
experimental part, mainly porous silicon, the methods used for
characterization, and the delivery of peptides and poorly soluble
drugs.
The first part of the chapter addresses the production and
properties of porous silicon and ordered mesoporous silicas.
Subsequently, the characterization of these materials is
discussed. The last part of the chapter surveys drug delivery
applications, starting from the production of loaded carriers to
the information that can be obtained about them by
characterization and, finally, to the actual drug release from the
carriers.
2.1 MESOPOROUS MATERIALS
Mesoporous materials have attracted significant and ever-
increasing research interest since the early 1990’s. They have
provided new possibilities over a wide range of applications not
only in areas from catalysis to electronics but also in drug
delivery by allowing manipulation of the internal structure of
materials in a nanometer range and by providing a large area to
promote various surface–guest molecule interactions.
By definition mesopores are pores with a diameter between
2–50 nm, while smaller pores are called micropores and the
5
6larger pores are termed macropores [12]. The term nanopore is
also sometimes used to describe mesopores as well as large
micropores  and  small  macropores,  but  this  does  not  have  a
generally accepted definition. In addition to the pore size, the
most important properties of the mesoporous materials include
their ability to control the pore size and wall thickness, the
regularity of their structure, and high surface area.
There are several types of mesoporous materials such as
mesoporous carbon, polymers and various metal oxides [13].
The most studied mesoporous materials in drug delivery
applications are silicon based: porous silicon (PSi) and porous
silica. These two materials are also those used in the present
study.
2.1.1 Porous silicon
As with many other scientific discoveries, such as penicillin or
Teflon, PSi was discovered by accident. It was first produced in
Bell Labs in 1956 by Arthur and Ingeborg Uhlir while studying
electrochemical etching of silicon and germanium, aiming at the
production of smooth surfaces [14, 15]. They noticed that a film
was produced on silicon with certain etching parameters, but
they were not aware of the porous nature of the film. It was only
15 years later when the true nature of this film was discovered
[16]. Very little research was conducted PSi during the 1970’s
and 1980’s. However, after an incubation of 20 years, wide
scientific interest in PSi was triggered by Leigh Canham’s
influential article in 1990, reporting the photoluminescence of
PSi at room temperature [17]. Further interest and possibilities
for a new range of applications emerged after another
pioneering article by Canham reported that porosification of
silicon could affect the biological behavior of the material [18].
The most widely utilized method of producing PSi for drug
delivery applications is electrochemical etching because it
provides the best control over the pore structure [19]. However,
recent progress in other methods, such as stain etching [20] or
metal assisted etching [21], should not be ignored, since these
techniques  might  provide  a  more  economical  way  for  mass
production  of  PSi  by  allowing  utilization  of  a  low-cost  raw
material and larger batch sizes.
The electrochemical etching of silicon is performed in an
electrochemical cell where a crystalline silicon wafer acts as an
anode and typically platinum metal as a cathode (Fig. 1). The
cell is filled with an electrolyte containing hydrofluoric acid
(HF). High anodic currents produce smooth silicon surfaces in a
process called electropolishing. With lower anodic currents
pores are etched on the surface of the silicon producing a porous
film.
Figure 1. Electrochemical cell used to produce porous silicon.
The formation mechanisms of PSi involved in the
electrochemical etching are very complex and are currently not
completely understood [19]. A simplified description of pore
formation can be made by considering the three processes
independently: dissolution of a silicon atom, pore initiation and
pore growth.
No significant dissolution of Si surface takes place in acidic
HF solutions in the absence of holes (empty electron state in the
valence band) in Si [22]. The otherwise reactive Si surface is
kinetically stabilized by the hydrogen termination of the surface
formed in HF solutions.
However, in the presence of holes, the dissolution of silicon
atoms can take place at the surface [22]. Holes are usually
generated either by an anodic bias or by illumination.
7
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holes are the minority charge carriers. The anodic bias causes
the holes to drift to the Si-electrolyte interface. A hole weakens
the Si-Si bond of a surface atom and the atom is dissolved by HF
following the overall reaction which takes place in the most
commonly studied conditions [22]:Si + 6HF + h? ? SiF??? + 4H? + H? + e?. (2.1)
In order for the surface to become porous, the etching must
take place selectively on the surface. If all the surface atoms
have an equal probability to dissolve, the surface would only
roughen and thus no pore formation would take place. It has
been postulated that certain features of the interface make some
silicon  atoms  more  likely  to  dissolve  than  others,  initiating  the
pore growth. These features include structural defects,
mechanically strained areas or local perturbations in the surface
potential field [19].
Once pores have been initiated, there must be a certain
mechanism (or mechanisms) to induce the etching to take place
preferably at the pore tips instead of the pore walls. Mechanisms
relying on either chemical properties of silicon or physical
mechanisms have been proposed [23]. The chemical
mechanisms propose that the local environment at the pore tips
makes the silicon atoms more reactive towards dissolution [23].
Some of the physical mechanisms involve a thinning of the
depletion layer. The depletion layer is a layer at the
semiconductor interface which is depleted from charge carriers.
The  thinning  of  the  depletion  layer  in  the  vicinity  of  the  pore
tips makes it easier for the holes to reach the surface atoms at
the pore tips as compared to the pore walls [23]. In addition,
passivation of the pore walls is also proposed to be due to the
depletion layer [24] or quantum confinement arising from the
narrow thickness of the pore walls [25]. Quantum confinement
effect causes an energy barrier for holes, consequently reducing
their probability to drift into the pore walls.
At present, there is no single all-encompassing “unified
theory of etching”. Indeed, its formulation would be a
formidable challenge because of the wide variety of PSi
structures that can be created under various conditions. The
structures can vary from microporous to macroporous, as well
as those with highly regular pores to pores with branched (Fig.
2) and sponge-like structures. The porosity can be anywhere
between 5 % and 95 % and surface area can range between 10
and 1000 m2/cm3 [19].
Figure 2. Scanning electron microscopy images of a cross-section of PSi. Pores are
aligned vertically and exhibit a branched structure.
There are numerous fabrication parameters affecting the
structure of PSi including the type and concentration of dopants
in silicon, crystallographic orientation of Si, composition of
electrolyte, illumination, current density, stirring of the
electrolyte and temperature [19]. Because of the high number of
parameters, their complex interdependency and lack of
theoretical understanding, the effect of different fabrication
parameters on the structure is mainly understood on an
experimental basis.
The structure of PSi can also be modified after the etching.
The annealing of PSi at a high temperature in an inert
atmosphere causes coarsening of the structure [26]. The driving
force for the process is the minimization of surface energy and
consequently of surface area as smaller pores become fused
together, forming larger pores [27]. The process becomes
kinetically possible at high temperatures because of the
increased mobility of Si atoms. The increased mobility is not
only due to the increased kinetic energy of the atoms but also
because of the changes in the surface chemistry. Surface
hydrides desorb at temperatures between 260 °C and 500 °C
9
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causing a reorganization of the surface and creation of dangling
bonds (unpaired electrons) which make possible the structural
changes [28].  The first signs of changes in the crystal structure
of PSi are observed at 350 °C but significant changes in the pore
structure take place at a temperature of 500 °C or higher when
most  of  the  hydrogen  has  desorbed  [28,  29].  It  should  be
mentioned that the structural changes taking place during
annealing occur in hydrogen terminated PSi, whereas oxidation
of the surface stabilizes the structure against coarsening [26].
In addition to the pore structure, another very important
feature of PSi, as of any other mesoporous material, is its surface
chemistry. The native surface of PSi after etching is hydrogen
terminated [30]. Mono-, di-, and trihydride species form a dense
layer at the surface. As mentioned earlier, the hydrogen
termination provides a passivating layer on the otherwise
highly reactive silicon. However, the passivation is not
complete, instead the hydrogen terminated PSi undergoes a
slow oxidation with oxygen or water molecules even under
ambient conditions [31]. In addition, hydride groups can act as
reducing agents for example with drug molecules loaded in the
pores [32]. Therefore, it is important to stabilize the surface in
order to produce a material with properties that do not change
as a function of time, and also a material that does not cause
undesirable changes to the guest molecules in the pores.
PSi is mainly stabilized via the addition of either oxygen or
carbon atoms in the structure. Both Si–O and Si-C bonds are
stronger and more stable than either Si–Si or Si–H bonds [33].
Therefore, a silicon oxide or silicon carbide layer on the pore
surface will efficiently stabilize the structure.
Oxidation of PSi is typically performed by thermal oxidation
or liquid phase oxidation. In thermal oxidation, PSi is heated in
an oxygen-containing atmosphere. Rapid oxidation begins at
250 °C with backbond oxidation of the Si–Si bonds of the surface
atoms [34, 35]. The surface hydrides are oxidized into Si–OH
groups at a slightly higher temperature because of the higher
bond strength of Si–H compared with Si–Si [35]. At a sufficiently
high temperature, 800 °C and above, complete oxidation of the
PSi structure into SiO2 is possible [36].
Another frequently utilized oxidation method is a liquid
phase oxidation with chemical oxidants such as H2O2 and HNO3
[37-39]. Furthermore, oxidation can be performed by removing,
at least partially, the stabilizing surface hydrides by annealing
and  subsequently  exposing  the  material  to  air,  which  causes  a
rapid oxidation of the surface [40].
Oxidation not only affects the surface chemistry, but it also
affects  the  pore  structure  of  PSi.  In  the  oxidation  process,  an
oxygen atom is added between two silicon atoms, causing a
volume expansion of the material. Therefore, decreased pore
volume and pore size have been observed after oxidation [41].
However, the effect of the oxidation on the pore size has not
been widely studied.
Stabilizing the PSi surfaces with carbon can lead to even
more stable structure than oxidation. Although the bond
strength of Si–C is lower than that of Si–O, it is more stable
because of the lower polarity of the bond, making it less
susceptible to nucleophilic attacks [30].
One beneficial method of generating highly stable Si-C
surfaces on PSi is thermal carbonization [42, 43]. This technique
is carried out by thermal decomposition of acetylene (HC?CH)
on a hydrogen terminated surface. At temperatures below 600
°C,  a  hydrophobic  hydrocarbon  surface  is  produced  by
desorption of hydrides and dissociation of acetylene on the
surface. The product is referred to as thermally hydrocarbonized
PSi (THCPSi).  At temperatures above 600 °C, the carbon from
acetylene penetrates into the structure of PSi forming a
nonstoichiometric silicon carbide layer on the surface. The
hydrophilic material produced is referred to as thermally
carbonized PSi (TCPSi).
2.1.2 Ordered mesoporous silica
The early history of another important type of mesoporous
materials, ordered mesoporous silicas, is curiously similar to
that of PSi. The first record of this type of materials can be found
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in a patent about the production of low density silica filed in
1969 [44]. Unfortunately, it was not known at the time that the
product was an ordered mesoporous silica, this fact was only
confirmed decades later [45]. These types of materials were
(re)discovered 20 years later in 1990 [46].  A highly influential
report of an ordered mesoporous silica MCM-41 (Mobil
crystalline material) was published by a group of scientists from
Mobil Research and Development Corporation in 1992 [47]. This
report sparked a wide interest in this type of materials, around
the same time that the research in PSi was rapidly increasing. A
further advance in development of the ordered mesoporous
silicas was the discovery of SBA-15 (Santa Barbara Amorphous),
which had a larger pore size, thicker pore walls and improved
hydrothermal stability [48].
The production of ordered mesoporous silicas differs
fundamentally from that of PSi. Whereas PSi is a so-called top-
down material in which the mesostructure is etched into bulk
silicon, the silicas are bottom-up materials, i.e., molecules are
assembled to form the mesostructure. The assembly is achieved
by using surfactant micelles as the template on which silica is
condensed [48].
A surfactant (i.e. surface active agent) is a substance that has
a tendency to adsorb onto surfaces and interfaces and
significantly alters the surface or interfacial free energy. These
substances  are  typically  molecules  with  hydrophobic  and
hydrophilic parts. In aqueous solutions of surfactants, free
energy is lowered when the hydrophobic parts of the molecules
pack together to minimize their interaction with water [49]. On
the other hand, the hydrophilic parts interact favorably with
water and form a layer surrounding the hydrophobic core.  The
formed aggregates can have different shapes e.g. spherical or
rod-like micelles, or lamellar structures depending on the
structure of the surfactant and the properties of the solution
such as concentration and temperature [49].
In order to synthesize SBA-15, micelles of amphiphilic
triblock copolymers are used as templates on which silica is
polymerized to form the pore walls [48]. The copolymer is linear
containing hydrophilic poly(ethylene oxide) end sections and a
hydrophobic poly(propylene oxide) middle section. The
formation of the SBA-15 structure has been observed to take
place via two distinct pathways. In the first pathway [50, 51], the
surfactant forms spherical micelles in the solution. Silica is
adsorbed and polymerized onto the surface of the micelles and
the spherical micelles form flocks. The micelles then start fusing
together forming rod-like structures, which eventually create
the hexagonally packed structure. In the second pathway [52],
surfactant  also  forms  spherical  micelles  in  the  solution.  The
spherical micelles become fused into rod-like micelles when
silica starts to adsorb and polymerize onto them. The rod-like
micelles form bundles and subsequently the bundles create a
hexagonal structure. After the formation of the hexagonal
structure, the surfactant is extracted by chemical dissolution or
by calcination at a high temperature [48].
The mechanism of the synthesis of MCM-41 is similar to that
of SBA-15, although there are also significant differences [47].
The key difference is that instead of the amphiphilic triblock
copolymers, smaller cationic surfactants are used as templates.
Thus, smaller pores are formed because of the smaller size of
template molecules. Because of the different template molecules,
the interaction between the surfactant micelles and silica
precursor differs in the synthesis of MCM-41 compared to the
synthesis of SBA-15. The interaction is electrostatic in its nature
in the MCM-41 synthesis whereas in the synthesis of SBA-15, the
interaction is believed to be due to electrostatic forces, hydrogen
bonding and hydrophobic attraction [50, 53]. Furthermore,
synthesis conditions are different for the two materials. For
example, while SBA-15 is synthesized under acidic conditions,
MCM-41 is synthesized under basic conditions [54].
SBA-15 has a well ordered structure of cylindrical pores
packed together in a 2D hexagonal structure (Fig. 3). The
mesopore size distribution is very narrow and the pore size can
be tuned in the range of 6 nm to 15 nm by changing the size of
the template polymer and altering the synthesis conditions [55].
In addition to the mesopores, the pore walls of the material
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contain micropores which are formed by polymer chains
embedded in the silica during the synthesis [56]. Another
interesting feature of SBA-15 is the presence of u-shaped pores
within the structure [57].
Figure 3. Scanning electron microscopy image of SBA-15 showing its pore structure.
The pore walls of SBA-15 consist of amorphous silica and the
pore  surface  contains  a  high  density  of  Si-OH  and  Si-(OH)2
species [53]. In addition to purely siliceous SBA-15, an
aluminum containing SBA-15 (al-SBA-15) can be prepared via
the addition of aluminum during synthesis [58].
2.2 CHARACTERIZATION OF MESOPOROUS MATERIALS
For successful development of mesoporous drug delivery
systems, thorough knowledge of their properties is essential.
The main properties to be characterized are pore structure (pore
size, pore volume surface area and pore morphology) and
surface chemistry. These properties have a major impact on the
behavior and applicability of the drug delivery system. For
example, the pore structure will affect the loading capacity of a
carrier and the release of drugs from the pores. Furthermore,
surface chemistry can affect e.g. loading of drugs and the
chemical compatibility between the carrier and the drug
molecules.
2.2.1 Pore structure
Electron microscopy is often used to examine the nanoscale
structure of mesoporous materials. Scanning electron
microscopy (SEM) is based on scanning a sample with a narrow
electron beam and recording the intensity of scattered electrons
at each point on the surface. This produces images of surfaces
with a three-dimensional appearance, making it possible to
visualize the surface structure, with resolution reaching 1 nm.
Transmission electron microscopy (TEM) reveals the internal
structure of materials by directing an electron beam through a
thin sample and then focusing a magnified image of the sample
on a fluorescent screen. The contrast of the images reflects
absorption of electrons in the sample. TEM makes it possible to
image fine details of materials thanks to a high resolution which
can reach atomic length scale. In this context, the greatest
advantage of these methods is their versatile ability to
determine pore morphology [59]. For example, the shape of the
pore cross-section and the pore walls as well as regularity of the
pore stacking can be observed. However, it can be very
laborious to obtain statistically significant values of the pore
diameter.
Gas sorption is probably the most common method to
measure the properties of the pore structure [60]. The basis of
the method lies in observation of a gas-liquid phase transition in
pores. In practice, an adsorption or desorption isotherm is
recorded  by  measuring  the  volume  of  a  condensed  gas  as  a
function of pressure under isothermal conditions. According to
the Kelvin equation, the condensation pressure is dependent on
the curvature of the liquid-gas interface and the curvature is
dependent on the diameter of the pore where the interface is
located. The BJH (Barrett Joyner Halenda) theory [61] is often
used to convert a recorded isotherm into a pore size
distribution. The pore sizes that can be measured with gas
sorption methods are between 0.5 – 200 nm [62]. An important
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advantage of the gas sorption methods is that, in addition to the
pore size and pore volume, surface area can be independently
calculated usually by BET (Brunauer Emmet Teller) theory [63]
which is based on observation of the multilayer adsorption of
gas on surfaces.  In addition to the quantitative analysis, also
qualitative information can be obtained about the pore
morphology. Features in the pore morphology cause
characteristic features in the adsorption and desorption
isotherms. An example of such a feature is an ink-bottle pore
(Fig. 4), in which a larger pore is connected to the exterior of the
particle by smaller pores (bottle necks) [64].
Thermoporometry is an interesting, although much less used,
method for characterizing mesoporous structures [65, 66]. In
thermoporometry, the liquid-solid transition in the pores is
observed and thus differs from gas sorption where the gas-
liquid transition is observed. Since freezing or melting
temperature inside a pore is dependent on its diameter, the
diameter can be calculated by measuring freezing or melting of
a substance in the pore. Furthermore, pore volume can be
calculated from the measured melting enthalpy of a substance in
the pores. Therefore, pore size distribution can be calculated
from a heat flow curve measured by differential scanning
calorimeter (DSC) over the temperature range of melting or
freezing. The pore sizes that can be measured by this technique
are typically in the mesopore range. However, up to 300 nm
pores have been measured [67]. In order to obtain a better
understanding of the method and results presented later, some
confinement effects on properties of materials in mesopores are
discussed below.
Thermoporometry is based on the melting point depression
of confined materials [68]. When loaded in the pores, an
adsorbate is divided into numerous small individual parts i.e.
the adsorbate in a single individual pore forms its own
“particle”. Since the size of these particles is very small, they
have a large surface area to volume ratio A/V and this ratio has
an important impact on the melting temperature. The melting
temperature can be determined by the free energy of the system.
It can be divided into a surface and volume contributions in
which surface contribution favors liquid state and volume
contribution favors solid state. The surface contribution to the
free energy of the system becomes significant with high A/V
values of the particles in the mesopores and melting point is
shifted to lower values as compared to large particles [69]. In
analytical treatments, it is practical to use the surface curvature
?=dA/dV instead of the area-to-volume ratio. An equation which
relates the curvature to the melting point depression ?T is the
Gibbs-Thomson  equation:  ?T =  -K?, where K is often assumed
to  be  a  constant.  As  a  result,  by  assuming  the  shape  of  the
liquid-solid interface during phase transition, the pore size can
be calculated from the Gibbs-Thomson equation [68].
Typically, melting and freezing in the pores takes place at
different temperatures. By measuring this melting-freezing
hysteresis phenomenon one can gather information about the
pore morphology. The reasons for this hysteresis have been
discussed in the literature [68, 70, 71]. In their highly influential
article, Brun et al. suggested that the reason for the hysteresis is
the difference in the shape of the solid-liquid interface during
melting and freezing [68]. In the presence of a bulk solid phase
at the pore openings, freezing is nucleated from a bulk phase
and propagates via a hemispherical solid-liquid interface. In
contrast, during melting, the solid-liquid interface follows the
shape of the pores. Therefore, the curvature of the interface is
almost always smaller during melting than freezing, leading to
this hysteresis behavior.
Another reason for melting-freezing hysteresis is a presence
of ink-bottle shaped pores (Fig. 4) [71]. Smaller adjacent
segments (bottlenecks) can cause supercooling in a wider
segment of the pore. The reason behind this effect is that the
freezing in a certain segment of a pore must be heterogeneously
nucleated from previously frozen adjacent segments. If a
nucleation center is not present at an adjacent narrower
segment, the material in the wider segment cannot freeze, even
though this would be thermodynamically possible.
Heterogeneous nucleation is required since homogeneous
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nucleation in the pore is highly unlikely because of the small
dimension of the pore. Exceptions to this phenomenon are
temperatures at and below the homogeneous nucleation
temperature, at which the nucleation rate becomes high enough
for homogeneous nucleation to become significant. On the other
hand, melting can take place individually in each segment
without nucleation and, therefore, any solid in the pores does
not become superheated.
Figure 4. Freezing and melting in an ink-bottle pore. Freezing is delayed by the bottle
necks causing supercooling in the wider parts of the pore.
A striking feature of solids confined in pores is that the whole
volume of the pore is not occupied by the solid phase [65].
Instead, a thin liquid-like layer exists between the pore wall and
the solid core. This is called the ?-layer and it exists because it is
energetically more favorable for a liquid rather than for a solid
to wet the pore wall [72]. The thickness of the delta layer (?) is
mainly dependent on the interactions existing between confined
molecules and the pore wall [73]. The ?-layer is typically two to
three molecule layers thick and can therefore occupy a
significant part of the pore volume within a narrow pore [65].
When using thermoporometry to determine pore sizes, it is
important to take into account the ?-layer. Since the radius that
is calculated by the Gibbs-Thomson equation (Rc) is the radius of
the crystal inside the pore and the pore radius (Rp) is
determined by the following equation Rp = Rc + ?. The thickness
of the ?-layer is often calculated using experimentally
determined volume of the crystalline part of the adsorbate and
the total volume of adsorbate and an assumed pore geometry.
X-ray diffraction (XRD) can also be used to measure structure
of porous materials. Since XRD provides information about long
range ordering of a material, a different type of information is
obtained when investigating ordered mesoporous silicas and
PSi. In ordered mesoporous silicas, atoms in the pore walls exist
in a disordered state. On the other hand, the pores exhibit long
range ordering. In accordance with Babinet’s principle,
diffracted radiation from a porous material is identical in
intensity but opposite in phase to “an inverse material” in which
the material and empty space are inverted in comparison with
the porous material. Therefore, the diffraction pattern of SBA-15
is similar to the diffraction pattern of hexagonally ordered rods.
The pattern contains information about the distance between
adjacent pores, arrangement of the pores and the quality of the
long range order. For example, the 2D hexagonal ordering of
SBA-15 can be confirmed by indexing the diffraction peaks in
the diffractograms. At least three diffraction peaks (from planes
[100], [110] and [200]) should be observed at low Bragg-angles
[53].
In contrast to the situation with ordered mesoporous silica,
PSi does not typically exhibit ordering of the pores but the
atoms in the pore walls are ordered in a crystalline structure.
Therefore, the information obtained from PSi is related to the
properties of the crystal e.g. distances between atoms and
crystallite size. A typical diffraction peak of PSi consists of a
sharp peak superimposed on a wide diffuse scattering [74]. The
sharp peak arises from the long range crystalline ordering of the
material. The origin of the diffuse scattering is more
controversial. According to Buttard et al., this is due to small
crystals, i.e. crystallites, present in the material and the width of
the diffraction peak reflects the crystallite size [75]. However,
Bensaid et al. argued that it arises from the pores following
Babinet’s principle [74]. According to this explanation, the width
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of a diffraction peak reflects the size of the regions lacking the
crystal structure, i.e. the pores and possible noncrystalline
surface layer.
2.2.2 Surface chemistry
Spectroscopic methods have been widely used to characterize
the surface chemistry of mesoporous materials. Probably the
most popular spectroscopic method in this context is Fourier
Transformation Infrared Spectroscopy (FTIR). This technique
can be used to measure absorption of electromagnetic radiation
in  a  sample  as  a  function  of  a  wavenumber,  using  an
interferometer. The absorption spectrum in the mid-infrared
region is especially useful since the spectrum contains
information about chemical bonds commonly found at the
surface of mesoporous silicon and silica, such as O-H, Si-H and
Si-O [76]. Each chemical bond can vibrate at certain
characteristic frequencies, and in most cases, there is a change in
the dipole moment of the bond related to the vibration. The
bonds only absorb photons with characteristic energies (and
thus wavenumbers) that exactly match the energy difference
between vibrational states of a molecule. These photons are able
to excite the molecule to a higher energy state and are
consequently absorbed.
Various other spectroscopic methods have also been applied
in the characterization of mesoporous materials. These include
Raman spectroscopy, which provides similar information as
FTIR, and nuclear magnetic resonance spectroscopy (NMR)
which can be used to characterize the chemical environment of
atoms [77, 78].
2.3 DRUG DELIVERY WITH MESOPOROUS MATERIALS
An  improvement  of  dissolution  of  poorly  soluble  drugs  by
loading into porous material was already reported in 1972 [79].
In that report, drugs were adsorbed onto the surface of fumed
silica. Fumed silica consists of small aggregated particles giving
rise to a large surface area and interparticle porosity.
Considerable scientific interest in mesoporous materials as drug
carriers was triggered in 2001 when Maria Vallet-Regi proposed
that MCM-41 could be used as a drug delivery vehicle to
achieve the sustained release of drugs [80]. The field has since
broadened to include improved release of poorly soluble drugs
[81], targeted cancer treatment [82] and gene delivery [83]. These
are only some of the new possibilities proposed for the
nanostructured materials during last decade.
2.3.1 Loading
Several therapeutically active small molecules have been loaded
into mesoporous materials [11, 81]. Poorly soluble drugs are
popular in these types of studies because their dissolution can
be readily enhanced by mesoporous carriers. In addition to
small molecules, peptides and proteins have been loaded into
mesopores in order to obtain a sustained release [84, 85].
Drug loading into mesoporous materials is commonly carried
out with solvents by either immersion or impregnation methods
[86, 87]. These methods are able to produce high drug loads at
room temperature.
In the immersion method, the carrier is immersed in an
excess of drug solution and drug is adsorbed onto the surfaces.
In addition to the adsorbed drug, some drug molecules exist in a
dissolved state in the pores. After the adsorption, the carrier is
filtered out of the solution and dried. It is relatively easy to
prevent extensive deposition of the drug on the external surface
of the carrier in this method by reducing the drug concentration
in the loading solution. However, the lack of precise control of
the drug load and drug wasted in the filtration step are viewed
as disadvantages of this method [86, 87].
The impregnation method begins by of addition of a drug
solution onto a carrier followed by evaporation of the solvent
which drives the drug molecules into the pores by diffusion [86,
87]. The term incipient wetness impregnation refers to a method
where the volume of the solution equals the pore volume [88]. A
true incipient wetness method results in rather low drug
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contents and is therefore not commonly used, although the term
is loosely applied for all impregnation methods [87]. The main
benefit of the impregnation method is the low amount of wasted
drug and the good control over the loading degree. However,
the presence of drug deposited outside the pores can be
problematic because the benefits of using the mesoporous
carrier are realized only for the portion of drug that is located
inside the pores [86, 89]. Drug on the external surface of
particles is especially disadvantageous for delivery of poorly
soluble  drugs  because  the  slowly  dissolving  drug  on  the
external surface prevents access of the release medium to the
pores.
2.3.2 Characterization of loaded mesoporous carriers
The following aspects of drug loaded mesoporous carriers need
to be characterized in order to understand their behavior;
amount of loaded drug (loading degree), chemical state,
physical state and the release profile of the drug.
The amount of drug in the carrier is usually determined by
thermogravimetry (TG) or by dissolving the drug in a solvent
and  analyzing  the  drug  concentration  of  the  solution,  e.g.,  by
high performance liquid chromatography (HPLC) or ultraviolet-
visible  spectroscopy (UV/VIS)  [81].  TG analysis  is  based  on  the
differences in the thermal degradation temperatures of the
carrier (typically inorganic) and the drug (organic). By heating
the sample above the drug degradation temperature while
recording the weight of the sample, the drug loading degree can
be calculated.
Because of the high pore volume and surface areas, high drug
loads in the materials can be achieved and drug loading degrees
up to 60 % have been reported [89]. The drug loading degree is
defined here as the mass of drug in the carrier divided by the
total mass of the loaded carrier.
It is important to characterize the chemical state of the drug
in order to determine whether degradation has taken place in
the drug carrier. Drug degradation is typically evaluated by
dissolving  the  loaded  drug  and  analyzing  the  solution  with
HPLC [90]. Many studies, that assessed the chemical integrity of
the loaded molecules, reported the drug to remain chemically
intact [11, 91]. However, more problematic drug–mesoporous
carrier combinations, resulting in chemical instability of the
drug, have also been described [11, 90, 92].
The chemical state of drugs is also characterized in order to
assess if the drug has chemisorbed on the pore walls, i.e.,
whether a chemical bond has formed between the pore wall and
the  drug  molecule.  Chemisorption  of  a  guest  molecule  on  a
carrier surface can be determined by adsorption-desorption
experiments where chemisorption is revealed by the irreversible
adsorption of the molecule on the surface [93]. It is also possible
to determine chemisorption spectroscopically by observing if
changes in chemical bonds have occurred during adsorption
[94].
The physical characterization of the drug loaded carriers
provides information about ordering of the drug
(crystalline/amorphous) and its location in the carrier. The drug
can exist in four distinct forms: crystalline outside the pores,
nanocrystalline inside the pores, amorphous or sparsely
dispersed on the pore walls. The amorphous form in the pores
can be present as a ?-layer between the crystal and the pore wall
or as the only phase in the pores.
Since the pore structure restricts the size of any crystals in the
pores, any large crystals found on the sample must be located
outside the pores [95]. The size of the crystals in the pores can be
detected with DSC because of the above mentioned size
dependent depression of the melting temperature. Therefore,
melting of drug detected at the bulk melting temperature is
evidence of drug crystals outside the pores and melting at lower
temperatures points to a nanocrystalline phase inside the pores.
If the drug is not in a crystalline state, a glass transition
should be detected with DSC provided that the drug is forming
amorphous clusters in or outside the pores [87]. In addition, the
glass transition temperature may change if an amorphous
material is confined within the pores [96]. On the other hand,
the absence of melting and glass transition implies that the drug
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is deposited on the pore surfaces without formation of larger
clusters [87].
Some information about the location of the drug can also be
obtained by measuring the pore size and pore volume of drug
carrier with gas sorption before and after loading [87]. A
reduction of  the pore size points to a formation of  a drug layer
on the surface of the pores. If the pore size is not affected, but
the pore volume is decreased, then the pores are partially
blocked by the drug but an adsorbed layer has not formed on
the pore walls. If there is no porosity detected after loading, then
pores are most probably blocked by the drug.
In  most  of  the  reports,  especially  with  mesoporous  silica
SBA-15 and MCM-14, loaded drugs have been detected in a
disordered form inside the pores [11, 87, 89, 97]. Although an
amorphous phase is thermodynamically unstable as compared
to its crystalline counterpart in bulk, the stability of a disordered
phase  in  mesopores  is  usually  found  to  be  good  since  no
crystallization has been observed even in humid atmospheres
after storage of several months [11, 98, 99]. The crystal growth is
prevented by the small dimensions of the pores where the drug
is located. A crystal nucleus has to reach a certain critical size in
order for crystal growth to be energetically favorable [100]. If the
pore size is smaller than this critical size, the crystals cannot
form inside the pores and the amorphous phase is stabilized.
However, in larger pores with a diameter above 10 nm, there are
also reports of the presence of drug in the crystalline phase [95,
101].
Mellaerts et al. reported that the loading method influenced
the location of the drug in mesoporous materials [87].
Impregnation of SBA-15 with a concentrated itraconazole
solvent resulted in molecularly dispersed drug on the pore
walls. On the other hand, impregnation with a dilute
itraconazole solution resulted in the formation of amorphous
clusters of the drug in the pores. Independent of the
concentration of the solution, ibuprofen was molecularly
dispersed on the pore walls.
The surface chemistry of mesoporous materials has been
found to affect the structure and biological activity of adsorbed
proteins [102]. This result highlights the importance of
compatibility between the guest molecule – pore surface and the
determination of biological activity of the loaded molecules.
2.3.3 Drug release from mesoporous carriers
The principle of measuring an in vitro release profile of drugs
from carriers is simple. Drug loaded carriers, often in a powder
form, are immersed in a release medium and the concentration
of  the  drug  in  the  medium  is  measured  as  a  function  of  time.
There is a wide variety of different methods available with
which to evaluate the dissolution process [103]. These methods
can vary depending on the type of release medium and its
volume, and the technique and rate of stirring. The
concentration of the drug in the release medium can be
measured by taking small samples or it can be assayed
continuously in the dissolution vessel. It is important to separate
the solid materials from the release medium when measuring
the dissolved concentration [103]. This can be achieved by
membranes, sedimentation or centrifugation.
It should be noted that the above mentioned simple in vitro
dissolution methods often do not correlate well with the in vivo
release. The system is very complex in the in vivo environment
because of the numerous chemical substances present, the
varying mechanical stimulus and the interactions between the
carrier and living cells. Therefore, simple in vitro release
experiments are more useful for determining properties of the
delivery system rather than assessing its behavior in the final
application in vivo.
Numerous combinations of potential drug carriers and
poorly soluble drugs have been tested in release experiments
[11, 81, 104]. The release rate of the drugs has been consistently
found to be improved significantly as compared with the
dissolution  rate  of  the  pure  drug.  For  example,  75  %  of
furosemide loaded into PSi was released within 60 min
compared  to  only  5  %  from  pure  crystalline  drug.  It  has  also
25
26
been demonstrated that release of poorly soluble drugs from
mesoporous carriers can produce supersaturated concentrations
in the release medium [105].
The improvement in the release behavior is attributed to the
disordered or the nanocrystalline state of the drug or to the
large surface area in from which the drug can be dissolved [10,
101]. As stated earlier, the drug is often present in a disordered
state in the pores. Since a disordered material is at a higher
energy state compared to a crystalline form, the apparent
solubility is significantly increased [106]. The apparent solubility
will also be increased if crystals are formed in the pores because
of the small size and consequently the large curvature of the
crystals [107]. The high apparent solubility leads to higher
dissolution rates [108]. On the other hand, the high surface area
in contact with release medium also increases the dissolution
rate. A high surface area is achieved when the drug is located on
the pore walls, leaving free the center of the pore.
It should be noted that apparent solubility refers to the
saturation concentration that can be formed by dissolution of a
solid that is not in its most stable form [109]. This should not be
confused with equilibrium solubility i.e. a true thermodynamic
solubility, which is the concentration of a substance in a solution
in equilibrium with the most stable solid form. The apparent
solubility  of  a  drug  depends  on  the  solid  form of  the  drug  but
this is not the case for the equilibrium solubility.
In peptide/protein delivery, a sustained release is preferred
because of the short duration of activity of these compounds [7,
9]. Sustained release can be achieved with mesoporous carriers
[110, 111], even though it might be difficult to appreciate why
that the same carrier can be used to enhance the release for some
compounds but also to delay the release of other compounds.
The sustained release from mesoporous carriers is attributed to
the relatively strong adsorption of the molecules onto the pore
surfaces and their slow diffusion in the narrow pores [110].
Because of the high surface area of the mesoporous carriers,
there may be a high number of molecules in direct contact with
the pore surface. The attachment can be due to hydrogen
bonding, electrostatic attraction, van der Waals forces or
hydrophobic interactions. Covalent bonding can also be utilized,
but  it  must  be  carefully  designed  in  order  to  ensure  that  the
structure of the released molecule remains functional. The
sustained release of proteins and peptides is also facilitated by
the properties of these molecules. They tend to be “sticky”
because they can have regions with divergent properties such as
hydrophobic, hydrophilic areas and positively and negatively
charged parts etc. [112]. Furthermore, these molecules can adopt
different conformations to accommodate to the features of the
surfaces [112].
Several parameters affect in vitro release rate of drugs from
the mesoporous carriers. Strong surface – drug interactions are
known to reduce the release rate [113, 114]. A well known
example is delayed release of ibuprofen from a carrier modified
with amino groups as a consequence of a coulombic attraction
between protonated amino groups on the surface and
deprotonated carboxylic acid group of ibuprofen [115, 116].
The pore structure has also an important effect on the release.
A decrease in pore diameter has been found to reduce the
release rate in pores under 13 nm in diameter. [89, 117]. This
effect is attributed to diffusion restrictions or purely to drug -
surface interactions [89, 118]. Although a large pore size can
facilitate fast release from the carrier, it can also promote
crystallization  of  a  drug  in  the  pores.  The  presence  of  drug
crystals in pores has been found to decrease the release rate as
compared with the amorphous state [101]. If crystalline material
is present on the surface of the pores, it can have a decelerating
effect on the release rate, especially with poorly soluble drugs
[10]. Furthermore, pore shape and interconnectedness have been
reported to affect the release rate. For example, small pore
openings hindered the release whereas interconnectedness of
the pores facilitated the release [104, 117].
A sustained release can be achieved by compressing
mesoporous powders into tablets [80, 117]. The compression of
particles with diameters in the range of microns into tablets with
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dimensions in millimeters significantly delayed the diffusion of
the guest molecules from the structure.
Although in vitro dissolution testing can be useful in
assessments of the drug carriers, more relevant results can be
obtained by in vivo testing. Despite numerous promising in vitro
studies, there are still relatively few reports of in vivo delivery of
poorly soluble drugs with mesoporous carriers [87, 91, 97, 119-
123]. In these studies, the bioavailability of a drug has been
assessed by measuring the drug concentration in plasma after
oral administration. Improved bioavailability compared with
pure drug has been observed in all of these published studies. In
comparison with commercial formulations used to enhance
bioavailability, improved or a comparable bioavailability has
usually been reported with mesoporous carriers. As much as a
fourfold increase has been observed in bioavailability with a
mesoporous carrier as compared with a commercial formulation
[121].
In addition to oral administration, mesoporous drug carriers
have been used to deliver various therapeutic agents via
parenteral routes [124, 125]. There is considerable interest in
using these carriers in cancer therapy [124, 126].
A beneficial way to evaluate a performance of a drug
formulation  is  to  measure  a  physiological  response  to  the  drug
after its administration. This is especially important when the
administered drug is a peptide or a protein since these
compounds can easily lose their bioactivity through degradation
or after changes in their three-dimensional folding.  Recently,
the physiological response to a few peptides released from PSi
has been studied, demonstrating that they achieved a sustained
physiological effect [127, 128].
3 Aims of the study
Preclinical development of mesoporous materials as drug
delivery systems includes the production of carriers, the
characterization of unloaded and loaded carriers, and the
evaluation of drug release from these structures. In the present
work,  all  four  aspects  have  been  studied.  The  specific  aims  of
the study were:
1. To develop a method to achieve the controlled enlargement
of pores in PSi by thermal annealing.
2. To assess the effects of various oxidation methods on
structure and surface chemistry of PSi and to develop
oxidation methods for producing inert surfaces on PSi with
minimal changes in the pore structure.
3. To develop a method for quantifying the amount of u-
shaped pores in SBA-15.
4. To provide detailed knowledge of the physical state of a
drug in the pores of PSi with various surface chemistries
and different pore sizes.
5. To determine whether PSi could be used as a carrier to
achieve sustained release of a peptide.
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4 Experimental
An overview of materials and experimental procedures used in
the present work is presented here. A more detailed description
can be found in the original publications.
4.1 MATERIALS
PSi was produced from boron doped Si wafers with resistivity
of 0.015 ?cm – 0.025 ?cm (I and V) and 0.01 – 0.02 ?cm (II and
IV). The wafers were 100 mm in diameter and the etched surface
was oriented along the crystallographic plane (100). The
electrolyte used in etching was a mixture of ethanol (99.5 %) and
HF (37 %–39 %) with ratios 2:3 (I), 1:1 (I, II and V) and 4:5 (IV).
MCM-41 was produced with cetyltrimethylammonium
bromide as the structure directing template, and fumed silica,
tetramethyl ammonium silicate and sodium silicate as the silica
sources.
SBA-15 was produced with Pluronic P123 triblock copolymer
as the structure directing template and tetraethyl orthosilicate as
the silica precursor in the presence of hydrochloric acid. In the
aluminum containing Al-SBA-15, aluminum isopropoxide was
used as the source of aluminum.
Two poorly soluble drugs, cinnarizine (II) and ibuprofen (IV)
and a peptide ghrelin antagonist (GhA, [D-lys-3]-GHRP-6) (V)
were used as model compounds. Cinnarizine is an antihistamine
and ibuprofen an anti-inflammatory drug. GhA blocks ghrelin
receptors and causes a reduction in the food intake and an
elevation in blood pressure. It is a relatively small (930 g/mol)
peptide consisting of six amino acids (H-His-D-Trp-D-Lys-Trp-
D-Phe-Lys-NH2).
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4.2 METHODS
4.2.1 Porous silicon
All PSi was prepared by electrochemical etching in a type of cell
presented in Fig. 1 with current densities of 20 mA/cm2 (I and IV)
and 50 mA/cm2 (I,  II,  IV  and  V).  A  high  current  pulse  was
applied at the end of the etching to dissolve the silicon between
the porous film and the silicon wafer in order to make it easier
to remove the porous film. The porous film was dried at 65 °C
and subsequently ball milled to produce PSi microparticles. In
article II, both free-standing films and microparticles were used.
After milling, the PSi powder was sieved into separate desired
particle size fractions. Since milling causes oxidation of PSi
surface, the powder was treated with a 1:1 mixture of HF and
ethanol to replace the oxide surface with hydrogen termination.
Annealing was carried out with hydrogen terminated
particles in a quartz tube in a tube oven (I, II and IV). A
continuous  nitrogen  flow  of  1  l/min  was  applied  while  the
sample was heated to temperatures between 400 °C and 1000 °C.
In this study, annealing is defined as heating in an inert
atmosphere (nitrogen gas), not to be confused with thermal
oxidation in which the sample is heated in air.
Surface stabilization was performed to PSi by oxidation,
thermal hydrocarbonization or thermal carbonization. Thermal
oxidation was performed by heating the PSi at 300 °C for 2 h
(IV). In article II, several oxidation methods were performed,
varying from thermal oxidation to liquid phase oxidation and
high temperature annealing followed by exposure to ambient
air.
Thermal hydrocarbonization was performed by continuous
flushing  with  a  1:1  mixture  of  acetylene  and  nitrogen  gases  (2
l/min) at 500 °C for 15 min. In thermal carbonization, the first
step was identical to thermal hydrocarbonization and in the
second step, the sample was flushed with the 1:1 mixture of
acetylene and nitrogen at room temperature followed by
heating the sample at 820 °C in nitrogen flow (1 l/min).
4.2.2 Ordered mesoporous silica
Reagents were inserted into an autoclave and synthesis was
carried out at 100 °C (SBA-15 and MCM-41) and 110 °C (Al-SBA-
15). After the completion of the synthesis, the material was
washed, dried and calcined at 500 °C–600 °C. All the
mesoporous silica samples were provided by the Department of
Chemical Engineering, Åbo Akademi, Turku, Finland.
4.2.3 Loading
PSi particles were loaded with ibuprofen with the immersion
method (IV). The particles were immersed in an ethanol solution
of ibuprofen (350 mg/ml). After one hour of immersion, the
particles were filtered out of the solution and dried at 65°C.
GhA was loaded with a similar method. The peptide was
dissolved in methanol and sonication was used to ensure
homogeneous  loading.  The  drying  was  performed  at  room
temperature.
4.2.4 Analyses
Thermogravimetry was utilized to measure the drug loading
degree in IV and V. Samples were heated up to 700 °C or 800 °C
at 20 °C/min in a nitrogen flow of 200 ml/min.
DSC  was  used  to  measure  melting  of  ibuprofen  in  PSi  (IV)
and melting/freezing behavior of water in MCM-41 and SBA-15
(III). Melting of ibuprofen was measured by heating the sample
from -60 °C to 115 °C with heating rate 10 °C/min. To measure
freezing/melting of water in mesoporous silica, the porous
powders were mixed with water with mass ratios of 1:3 or 1:2
(porous silica: water) and the samples were sealed in aluminum
crucibles. Freezing of water was measured by cooling the
sample from -0.5 °C to -70 °C and melting of water from -70 °C
to 10 °C at a cooling/heating rate of 1 °C/min. The water outside
the pores was frozen prior to the measurement. All DSC
measurements were conducted under nitrogen flow (40
ml/min).
In all of the articles, mesoporous samples were characterized
by gas sorption. Adsorption and desorption of nitrogen were
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performed at liquid nitrogen temperature. The pore size was
calculated from desorption branch using BJH-theory and surface
area from adsorption branch using BET theory. Total pore
volume was calculated from a single adsorption point after
capillary condensation in mesopores. The primary mesopore
volume was calculated with the BJH theory and micropore
volume by t-plot analysis (III).
The thickness of the oxide layer was estimated by measuring
the pore size of the of oxidized PSi samples by gas sorption
before and after dissolving the oxide by HF (II).
X-ray diffraction measurements were preformed with Bragg-
Brentano geometry. In articles I and III, powdered samples were
compressed on a sample holder, whereas in article II, PSi films
were used in a horizontal position (reflection configuration) or
vertical position (transmission configuration).
The pore morphology was imaged with SEM. Samples were
measured as such, without metal coating. The cross-section of
PSi films was imaged from freshly fractured surface (II) whereas
mesoporous silica samples were imaged in a powder form (III).
FTIR was used to characterize the surface of PSi in article II.
The FTIR spectra were measured in the transmission mode
through PSi films. The spectra were recorded in a range from
500 cm-1 to 4000 cm-1 with resolution 4 cm-1.
Isothermal titration microcalorimetry was used to measure
adsorption enthalpy of model drug cinnarizine on oxidized PSi
surfaces in the article II. Prior to the measurements, ethanol was
added into sample and reference ampoules and PSi
microparticles into sample ampoule. The measurements were
conducted by injecting the ethanol solution of cinnarizine
simultaneously into sample and reference ampoules and
measuring the difference in the heat flow signals between the
ampoules. Because the only difference between the sample and
reference sides was the presence of PSi in the sample ampoule,
the recorded heat flow signal was interpreted to arise from
energetic interactions between PSi and cinnarizine.
5 Results and discussion
5.1 ENLARGEMENT OF PORES IN POROUS SILICON BY
ANNEALING (I)
Therapeutic molecules that can be loaded into PSi vary in size.
The size of small molecules can be less than a nanometer
whereas proteins can be tens of nanometers in size. Therefore, in
order to utilize PSi as a carrier for a wide variety of molecules,
also the size of the pores has to be adjustable. Pores of different
sizes can be produced by electrochemical etching. However,
etching pores in a wide range of pore sizes often encounters
practical difficulties. Such difficulties can involve purchasing Si
wafers with different doping levels, using high current densities
in etching or using different etching setup (e.g. etching with
backside illumination). Because of these difficulties, it is
practical to perform etching with a standard method and to
adjust the pore size after etching. Annealing hydrogen
terminated PSi in an inert atmosphere is a useful method for
such adjustment.
The effect of annealing on PSi was studied to utilize
annealing for controlled enlargement of pores. It was found that
the pore size could be controlled from 10 nm up to 80 nm by
adjusting the annealing temperature between 400 °C and 900 °C
(Fig. 5). The higher the temperature, the larger was the pore size.
The enlargement of the pores was found to be sensitive towards
the porosity of PSi. The pore size of highly porous (83 %) PSi
experienced significantly larger changes compared with PSi
with lower porosity (70 %) (Fig. 5).
The lower limit of annealing temperature at which structural
changes are observed coincides with those reported in the
literature [28]. The extent of pore enlargement was higher than
observed  by  Müller  et  al.  which  is  easily  explained  by  the  low
porosity (20 %) of their material [27]. However, the calculated
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activation energies were similar to the ones obtained by Müller
et al. despite the different porosities.
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Figure 5. The effect of annealing temperature on the pore size of porous silicon. The
results of two samples with different initial porosities (70 % and 83 %) are presented.
In addition to the increase in the pore size, also the width of
the pore size distribution increased with the increasing
annealing temperature. For example, the full width at half
maximum values for Gaussian peaks fitted according to the
pore size distributions increased from 8 nm to 48 nm for the
sample with a porosity of 70 % annealed at 900 °C. The increase
in the width of the pore size distribution is expected because of
the randomness of the process of fusing the pores.
The structural changes were completed within 45 min in
almost all experiments with no further changes observed with
prolonged treatment. The rate of structural changes became
faster at high temperatures. The structural changes were
completed in 20 min at 800 °C whereas at 400 °C it took 90 min
despite the small extent of the changes. Müller et al. reported the
changes in the pore diameter to follow simple power law ? ? ?
?
?,
where t is time [27]. They observed significant changes in the
pore diameter between 60 and 120 min even at annealing
temperatures of 1000 °C and did not observe completion of
changes. The significantly slower rate of pore diameter change is
most likely due to the low porosity and thicker pore walls in the
material used by Müller et al. In order for the coalescence of
pores with thick walls to take place, the extent of atomic surface
diffusion needs to be much higher compared with the material
with thin pore walls.
Surface area was found to decrease as a natural consequence
of the enlargement of the pore size. In addition, pore volume
decreased with increasing annealing temperature. This is most
likely  due  to  closing  of  the  pores,  creating  pores  that  are  not
connected to the external surface.
Changes in crystal structure of PSi caused by annealing were
observed by XRD. Large changes in the crystal structure took
place at a high annealing temperature. The diffraction intensity
from {111} planes was at a minimum at an annealing
temperature of 600 °C and was recovered at higher
temperatures. Interestingly, diffraction intensity from
crystallographic {400} planes was decreased as a function of
annealing temperature, almost disappearing at 900 °C. There
was no significant change in the baseline level, indicating that
no amorphous phase had been formed. Similar results were
obtained by Ogata et al. although comparison of results is
difficult because of the small number of annealing temperatures
used by Ogata et al. [28].
Annealing was found to be a useful method of producing PSi
with distinct pore sizes. The resulting pore size can be
controlled with annealing temperature. The method is especially
beneficial when producing a series of PSi samples with various
pore sizes. These results were utilized in article IV to produce a
series of PSi samples with distinct pore sizes between 10 nm and
75 nm.
37
38
5.2 OXIDATION OF POROUS SILICON (II)
High surface area and pore volume as well as inertness towards
guest molecules are beneficial properties for a mesoporous drug
carrier. To ensure the inertness, the surface needs to be
stabilized which is most often achieved by oxidation. However,
oxidation reduces the surface area and the pore volume because
of the volume expansion of the surface which occurs during
oxidation. Therefore, it was considered desirable to develop an
oxidation method that would produce inert surfaces but cause
minimal changes on the pore structure.
A large number of oxidation treatments were used to oxidize
PSi. The primary aim was to produce surfaces free from hydride
groups (Si-Hx) because of their reactivity. The oxidation in the
liquid phase without high temperature treatments was found to
be unable to produce surfaces completely free from hydrides.
This  is  most  likely  due  to  steric  hindrances.  The  surface  of  PSi
has high hydride coverage after production with mono-, di- and
trihydrides  present  at  the  surface.  Oxidation  of  all  hydrides  to
hydroxyl groups (Si-OHx) cannot take place because of
increasing steric constraints as the oxygen atom is added into
the structure. On solid surfaces, Si-OH3 groups are rarely found
and therefore, some hydrides are always left on the surface.
There are reports claiming complete or almost complete
removal of hydrides with liquid phase oxidation [129, 130]. It is
likely  that  this  discrepancy  is  due  to  the  thickness  of  the  PSi
films used in the FTIR measurements. The films with thickness
of  ~  100  µm were  used  in  this  work  to  achieve  high  sensitivity
towards low quantities of chemical species. Thinner films were
used in the studies by Fukuda et al. and Li et al. and this might
explain why no hydrides were detected.
In order to produce surfaces free of hydrides, it was found
necessary to apply a heat treatment. Heat treatment evokes
desorption of hydride groups and reordering of the surface,
consequently, reducing steric crowding. When there are fewer
hydride  groups  on  the  surface,  it  is  possible  to  oxidize  the
remaining hydride groups.
Three methods involving heat treatments were able to
produce hydride-free surfaces: thermal oxidation at 700 °C
(sample 1, S1), the combination of thermal oxidation (300 °C)
and annealing (1000 °C) (S2), and the combination of thermal
oxidation  (300 °C), annealing (750 °C) and liquid phase
oxidation (S3). These methods were optimized to produce as
small changes as possible into the pore structure. A thermally
oxidized (300 °C, 120 min) sample TO120 containing hydride
groups was produced as a reference.
Structural and chemical properties of samples 1, 2 and 3 were
compared  (Fig.  6).  Sample  1  had  a  thick  oxide  surface  and  the
pore volume decreased by a third. Sample 3 exhibited smaller
changes in the pore volume and an insignificant change in the
pore size. Sample 2 displayed the smallest decrease in the pore
volume and an increase in pore diameter. However, further
investigation showed that the coverage of the oxide surface was
not sufficient to stabilize the surface and the material since the
sample experienced chemical changes upon storage under
ambient conditions.
The oxide thicknesses are very high compared to the reported
growth rate of thermal oxide layer on porous silicon 0.025
nm/min at 800 °C [131]. These values are for oxidation times > 1
h  and  PSi  with  wall  thickness  of  30  nm.  The  initial  rate  of
oxidation is much higher because of the easier diffusion of
oxygen in the structure. Jarvis et al. reported changes in the
surface area, pore volume and pore diameter caused by thermal
oxidation at various temperatures for 1 h [41]. They showed a
decrease in surface area, pore volume and pore diameter with
increasing oxidation time, in agreement with the results
presented here.
The chemical reactivity of these surfaces towards cinnarizine
was evaluated by isothermal titration microcalorimetry.
Samples 1 and 3 were found to exhibit small heat of adsorption
< 11 kJ/mol (measured heat associated with adsorption per
moles of injected cinnarizine) consistent with physisorption of
cinnarizine onto the surfaces. Despite the apparent similarity of
the surfaces on sample 1 and 2, sample S2 showed high heats of
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adsorption (52 kJ/mol) which was interpreted as a sign of a
chemical reaction associated with adsorption. The nature of the
chemical reaction between cinnarizine and S2 was not
determined. The heats of adsorption presented here are a lower
limit for the initial heat of adsorption of cinnarizine. The actual
values could be higher because all of the cinnarizine from the
solution might not adsorb onto the PSi surfaces. In addition, the
heats of adsorption were decreasing for subsequent injections,
which indicates that if smaller injections were used, the heat of
adsorption for the first injection would most likely be higher.
The results pointed to low reactivities for S1 and S3, but no
general conclusions could be drawn.
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Figure 6. Changes in properties of PSi caused by oxidation treatments. The changes in
pore diameter, surface area and pore volume caused by oxidation treatments are
presented. In addition, the adsorption enthalpy of cinnarizine on oxidized PSi surfaces
and the thickness of the oxide layer are shown. The samples were oxidized by following
treatments TO120: thermal oxidation (300 °C, 120 min), S1: thermal oxidation (700
°C, 7.5 min), S2 thermal oxidation (300 °C, 4 min) + annealing (1000 °C, 20 min) and
S3: thermal oxidation (300 °C, 4 min) + annealing (750 °C, 30 min) + liquid phase
oxidation (with last two steps repeated).
The comparison between samples thermally oxidized at 700
°C  for  7.5  min  (S1)  and  at  300  °C  for  120  min  (TO120)  was
particularly interesting. Although S1 had a thicker oxide surface,
it exhibited a smaller decrease in pore volume and diameter.
This could be explained by a swelling of the silicon skeleton
during the oxidation at 700 °C facilitated by the higher ductility
of the silicon. Whereas at 300 °C, the oxide had to grow towards
the pore centers, at 700 °C the swelling could partially
accommodate the volume expansion. This hypothesis was
supported by XRD measurements showing higher increase in
the size of voids in the silicon crystal in S1 sample compared
with TO120 sample.
A high temperature thermal oxidation (S1) was found to be a
beneficial method of oxidizing PSi. It produced inert surfaces
and thick oxide layers. The growth of a thick oxide layer could
be partially accommodated by swelling of the structure, and
therefore there were no dramatic changes in the pore structure.
The combination of thermal oxidation, annealing and liquid
phase oxidation (S3) preserved the pore structure better than a
high temperature oxidation. However, before applying this
method one should carefully consider whether the benefits in
the structure outweigh the longer time required for sample
preparation.
5.3 CHARACTERIZING U-SHAPED PORES IN SBA-15 (III)
The pore structure of mesoporous materials is important in drug
delivery applications because it affects loading and release of
drugs. SBA-15 has a tendency to form u-shaped pores to varying
degrees. U-shaped pores (Fig. 7) do not simply extend through
the particle but are folded back into the particle at the surface,
forming a u-shape. This increases the length of the pore
compared to straight pores that go directly through the particle
with openings at both ends. The increase in the particle size has
been found to decrease the release rate of a drug which is most
likely related to the increase in the pore length. Therefore, one
can hypothesize that the u-shaped pores would have a similar
release hindering effect. However, it is difficult to quantify the
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amount of these pores. Although they can be observed with
SEM it is very difficult to obtain any quantifiable estimate of the
proportions of straight and u-shaped pores.
Figure 7. SEM image showing u-shaped pores in SBA-15.
In article III, a novel method of quantifying the u-shaped
pores was developed. This method is based on measuring
freezing and melting of water in the pores by DSC. SBA-15 was
found to exhibit an unusual freezing–melting hysteresis where
freezing produced a single peak but the melting process was
split into two separate peaks, centered at different temperatures
(Fig. 8). There is a previous mention of this kind of hysteresis in
the literature but its origins were not explained [132]. We
assigned these two melting peaks to the melting of water in the
u-shaped pores and straight pores according to the following
explanation (Fig. 8). When the temperature of the SBA-15 with
pores filled with ice is increased, the ice in the curved part of the
u-shaped pore will melt at the lowest temperatures. This can be
either due to the high curvature of the outermost curved wall of
the pore (innermost wall forms a saddle surface with a low local
curvature) or defects in the ice crystal caused by the curve of the
pore. As soon as the curved part has melted, a new
hemispherical solid-liquid interface is formed. This interface has
a high curvature as compared with the cylindrical surface of the
ice in the straight parts of the pore. This high curvature makes
the interface unstable at the prevailing temperature and the ice
in the straight parts of the u-shaped pores melts instantaneously
after the melting of the ice in the curved part. In the straight
pores, melting is initiated at a higher temperature, i.e. when the
cylindrical interface of the ice becomes unstable. Therefore, the
peak at a lower temperature represents melting of ice in all
pores containing u-shapes and the peak at higher temperatures
represents melting in the straight pores. The ratio of volume in
the two types of pores is obtained by calculating the ratio of the
peak areas, since the area of a melting peak is equal to the
melting enthalpy.
Two melting peaks would also be observed if there were two
distinct pore sizes but this would produce two freezing peaks as
well, which was not observed. Instead, only one freezing peak
was detected, i.e. freezing takes place at the same temperature in
both pore types, consistent with the above interpretation. The
freezing is initiated by nucleation at bulk ice at the pore
openings  and  the  pore  openings  are  of  the  same  size  in  both
straight pores and u-shaped pores. The shape of the solid–liquid
interface is hemispherical and, therefore, the freezing
temperature is lower compared with the melting temperature of
ice in straight pores which is determined by of the curvature of
the cylindrical interface.
Interestingly, similar behavior was not observed in nitrogen
sorption measurements, although analysis of freezing and
desorption as well as melting and adsorption usually provide
similar results. A significant difference between the two
methods is that in melting/freezing experiments there is an
ordered phase (ice) present whereas in the gas sorption none of
the phases are ordered. This could mean that defects in the ice
crystals are responsible for the initiation of melting in the u-
shaped pores.
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Figure 8. Melting and freezing of water in the pores of SBA-15 measured by DSC. The
schematic reveals the mechanism behind the hysteresis phenomenon: A) melting of ice
in u-shaped pores, B) melting of ice in the straight pores and C) freezing in both types
of pores.
Different proportions of u-shaped and straight pores were
observed in different SBA-15 materials. The fraction of pore
volume  in  u-shaped  pores  was  (65  ±  1)  %  and  (27  ±  2)  %  in
siliceous SBA-15 and Al-SBA-15, respectively. A similar
phenomenon was not observed with MCM-41.
Since no other method can be used to measure proportions of
these pores, the values obtained here could not be quantitatively
validated. A qualitative support was obtained with SEM
imaging which revealed that more u-shaped pores could be
observed in SBA-15 than in Al-SBA-15. However, further
support for the validity of the method is not available.
5.4 PHYSICAL STATE OF DRUGS IN POROUS SILICON (IV)
The majority of articles about drug delivery with mesoporous
materials describe systems in which the drug is present in an
amorphous  form.  The  amorphicity  of  the  drug  is  often  due  to
the small size of the pores preventing crystallization. If there are
sufficiently large pores, then drugs are able to crystallize.
However, crystalline forms of drugs in the pores are not well
studied. It is important to be aware of the physical state of drugs
in the pores because it may affect physical and chemical stability
of the drugs and their release from the pores.
Eight PSi batches were produced with different pore sizes by
annealing at different temperatures and by surface oxidation
followed by etching the oxide with HF. The pore diameters were
in the range from 10 nm to 75 nm. Each of the eight batches was
divided into three samples with different surfaces: thermally
oxidized (TO), thermally carbonized (TC) and as-anodized (AA)
which is the hydrogen terminated surface. These samples were
loaded with ibuprofen and the melting of ibuprofen was
measured with DSC.
Ibuprofen was found to be present in crystalline state in all
the samples. Outside the pores, crystalline ibuprofen was only
observed in two samples and at minor amounts (< 0.1 % of total
amount of ibuprofen in the sample). Inside the pores, crystalline
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ibuprofen was found in all of the samples. However, in the
smallest pores, crystallization was found to be a slow process
that could take several weeks to reach a stable state. After
reaching the stable state, no further change was detected even
after several months.
A clear trend was observed, when the measured melting
enthalpy of ibuprofen was divided by the mass of ibuprofen in
the sample. The smaller the pores, the lower was the specific
melting enthalpy and the lower was the crystallinity of
ibuprofen. The crystallinity of ibuprofen varied between 39 %
and 94 %. This was assumed to be because of the non-crystalline
?-layer between the pore wall and the drug crystal. In order to
test this hypothesis and to evaluate the thickness of the layer, a
simple geometrical model of the system was devised (Fig. 9).
The pores were assumed to be cylindrical with diameter D and
the drug was assumed to fill the pore where it existed i.e. no
parts of the pores contained only a layer of the drug on the pore
walls. Ibuprofen at the center of the pores was in the crystalline
state and there was a ?-layer with constant thickness (?)
between the crystalline core and the pore wall. With this
geometrical model, and also assuming the specific melting
enthalpy of the crystalline part ?h to be equal to the bulk value
(125.9 J/g), the following equation between the measured
melting enthalpy (?H) and ? was derived:
??
?
? ?? ?? ?
??
?
?
?
, (4.1)
where m is the mass of ibuprofen in the sample. The values for ?
were obtained by plotting the ?H/m versus D and fitting the
equation (4.1) to the data points separately for each surface type
(Fig. 10). The thickness of the ?-layer was found to be 1.2 nm, 1.5
nm  and  2.0  nm  on  AA,  TO  and  TC  surfaces,  respectively.  The
values of ? can be considered as an indication of the strength of
the drug–pore wall interactions. The stronger are the
interactions, the further from the surface the effect extends and
the thicker is the ?-layer.
This work is the first report of the ?-layer thicknesses for
drugs in mesoporous materials. Azais et al. reported that, in
addition to the crystalline phase, some disordered ibuprofen
was always detected in the 11.6 nm wide pores of MCM-41 [133].
The thickness of ?-layer has been previously reported for simple
molecules which are usually used as probe molecules in
thermoporometry [65]. The reported thicknesses are typically in
the  range  of  2  –  4  monolayers.  The  present  results  suggest  a  ?-
layer of 1 – 4 monolayers (size of an ibuprofen molecule is
approximately 1.2 nm x 0.8 nm x 0.5 nm [133]).
Figure 9. The geometrical model of ibuprofen in pores of PSi devised in order to derive
the equation (4.1).
The nature of interactions between ibuprofen and the PSi
surfaces was not determined, but some clues could be obtained
by zeta potential measurements. The thickest ?-layer was found
with  the  TC  surface,  which  is  expected  to  be  oxidized  silicon
carbide surface. This surface had the greatest negative zeta
potential of the three tested surfaces. The TO surface is partially
oxidized and had the second most negative zeta potential. The
HT surface on the other hand, was only slightly oxidized by the
short exposure with air and had the least negative zeta potential
as well as the thinnest ?-layer. Therefore, it is possible that the
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carboxylic group of ibuprofen is forming hydrogen bonds with
the surface oxides of PSi.
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Figure 10. Graph showing the specific melting enthalpy of ibuprofen in the pores of
PSi versus the pore diameter. Equation 4.1 is fitted to the data points to obtain the
thickness of the ?-layer.
The validity of the assumption for ?h was tested by using it
as a fitting parameter. The values obtained were between 121 J/g
and 128 J/g and in good agreement with the assumption. The
values of ? from this fitting were not significantly different from
those obtained with fixed ?h.
The geometrical model is not totally valid especially for non-
annealed samples. It is well known that the pores in PSi are not
cylindrical, as assumed in the model, but have rather irregular,
branched  pore  walls  which  are  likely  to  be  smoothed  by
annealing. However, the fittings were reasonably good, which
seems to indicate that the errors due to the model were
moderate.
It was shown that both pore size and surface chemistry of the
carrier affect the crystallinity of ibuprofen in the pores.
Crystallinity is known to affects the dissolution rate of
macroscopic drug particles and, therefore, it seems reasonable to
expect that crystallinity would also influence the release of
drugs from mesoporous carriers. Indeed, it has been recently
observed that drug in a crystalline form in the pores was
released slower than a drug in an amorphous form [101].
However,  our  unpublished  work  has  shown  very  fast  release
rates of drugs in crystalline form from large pores.
There are several parameters affecting the release behavior of
drugs from a mesoporous carrier. The pore size affects
crystallinity and also diffusion of drugs from the pores.
Furthermore, the surface chemistry of the carrier not only
influences the crystallinity but also the release of drug molecules
that are in contact with the surface. Therefore, more work will
need to be done to truly uncover the optimal properties of the
mesoporous drug carriers.
5.5 POROUS SILICON IN SUSTAINED DELIVERY OF PEPTIDES
Peptides are promising therapeutic agents for several severe
illnesses. However, their applicability is often limited by their
short duration of activity in vivo. Therefore, there is a need for
novel delivery methods providing sustained delivery of
peptides in an active form.
Delivery of a peptide GhA from THCPSi microparticles was
studied in vivo. THCPSi particles were chosen because of the
stability of the surface preventing chemical reactions between
the surface and the peptide, and because of their hydrophobic
surface.  Peptide  can  be  bound  on  the  hydrophobic  surface  by
hydrophobic interaction and therefore a sustained release in an
aqueous medium can be achieved. The used particles had large
enough pore size (> 11 nm) to easily accommodate the peptide
molecules with molecular weight < 1000 g/mol and high enough
surface area and pore volume to provide loading degree > 15 %.
Animal  models  offer  the  most  realistic  way  to  study  the
applicability of the peptide loaded carriers. Furthermore, by
studying the physiological responses to the released peptide, it
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is possible to show in addition to the release of the peptide, that
the peptide remains biologically active.
Physiological  responses  to  the  peptide  were  followed  by
observing the food intake in mice and measuring the blood
pressure in rats after injections of GhA loaded THCPSi
microparticles. A vehicle, GhA solution or unloaded THCPSi
particles were injected as controls. The injections were given
subcutaneous (under skin), which is a suitable route because it
enables the adsorption of peptides (contrary to oral route with
most peptides), enables usage of > 38 µm particles and can be
done easily to conscious animals.
The effect of GhA solution on food intake lasted for 4 h.
However, GhA-loaded THCPSi particles were found to inhibit
food intake at the beginning of the experiment and between 7 h
and 17 h (Fig. 11). Cumulative food intake between 7 h and 17 h
was 0.203 g/g and 0.229 g/g (grams of food per grams of body
weight) for GhA-loaded THCPSi and GhA solution, respectively.
The loaded GhA maintained relatively stable elevation in blood
pressure in rats for 9h whereas the effect of GhA solution was
very high at 1 h but decreased back to the baseline in 10 h (Fig.
11).
Plasma cytokine levels were also tested after administration
of unloaded THCPSi particles. Elevated levels of cytokines are
indicative of inflammation or infections in the organism.
Significantly (p < 0.05) elevated cytokine levels were found only
for one cytokine at one time point. However, since a total of 30
time points was tested; this is likely to be an experimental
artifact.
These results indicated that THCPSi particles were releasing
an active form of GhA in a sustained manner without evoking
an inflammatory response. The physiological response to the
GhA-loaded THCPSi was rather weak and the duration of the
effect was not as long as would be required for the formulation
to be commercially interesting. Other techniques have been
reported to provide more sustained release of peptides after
subcutaneous injections [134, 135]. However, this was the first
report of in vivo peptide delivery with PSi, opening a pathway to
further development in this field.
Figure 11. Results of peptide delivery experiments showing change in blood pressure
in rats after subcutaneous administration of GhA, GhA loaded THCPSi microparticles
(THCPSi+GhA), vehicle and unloaded THCPSi microparticles (THCPSi).
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6 Conclusions
Several aspects of development of mesoporous materials as
drug delivery agents were studied, from material production to
characterization and finally to in vivo delivery experiments.
Thermal annealing of PSi in an inert atmosphere was found
to be a suitable method of increasing pore size from 10 nm up to
80  nm  in  a  controlled  manner.  The  pore  size  could  be
manipulated by adjusting the annealing temperature. The initial
porosity of the sample was found to have a major impact on the
extent of the pore size increase.
A wide variety of oxidation methods was evaluated for a
stabilization of PSi. Liquid phase oxidation was not able to
produce hydride-free surfaces. Oxidation at high temperatures
for  a  relatively  short  time  was  found to  be  a  beneficial  method
because it caused relatively minor changes in the pore structure
and generated surfaces that were not found to react with the
model drug. Smaller changes in the pore structure were
achieved with an elaborate method comprising of thermal
oxidation, annealing and liquid phase oxidation.
A novel method of quantifying u-shaped pores in SBA-15
was developed. The method was based on the unique hysteresis
phenomenon occurring between melting and freezing of water
inside the pores. No other method is known to be capable of
quantifying this property of SBA-15.
The physical state of ibuprofen in PSi with various pore sizes
and surface chemistries was characterized. The drug was found
to crystallize at the center of the pores and a non-crystalline
layer was formed between the crystalline part and the pore wall.
The thickness of this layer was dependent on the surface
chemistry of the pores. A method was developed to measure the
thickness of this layer. By varying the pore size and the surface
chemistry, the crystallinity of ibuprofen varied between 39 %
and 94 %.
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Thermally hydrocarbonized PSi microparticles were shown
to be able to deliver a biologically active form of a peptide
ghrelin antagonist in a sustained manner in vivo. The peptide
loaded carrier exhibited sustained effect on both food intake in
mice and blood pressure in rats after subcutaneous
administration. In addition, the PSi microparticles were not
found to evoke any inflammatory reactions.
These studies highlight the wide range of elements involved
in the development of mesoporous drug delivery systems. From
the production of the porous structure and design of the surface
chemistry to detailed characterization of such systems and
finally to the application of the systems in living organisms. The
pore structure and surface chemistry cannot be designed
independently as the modifications of surface chemistry can
have significant influence on the pore structure. Furthermore,
the pore structure and surface chemistry influence the physical
and chemical forms of the loaded drug. A thorough
characterization of the drug carrier and the drug in the carrier is
essential in understanding the delivery system. Conventional
analysis techniques are not always sufficient to detect all the
essential features of these delivery systems.
The knowledge related to mesoporous drug delivery systems
is increasing rapidly as new research papers in this field are
being published daily. However, there is still plenty of room for
new research. The present work provides some loose ends that
motivate future studies. The evolution of the structure of PSi at
the atomic level during annealing and thermal oxidation
requires more systematic studies in order that it can be
understood in detail. Moreover, evaluating the effect of pore
size, surface chemistry and thickness of the ?-layer on the
release profile of poorly soluble drugs would be particularly
interesting and might provide further insights in these drug
delivery systems. The effect of u-shaped pores on the release
rate of drugs has not been determined so far, although this kind
of study would be now feasible on the basis of the present
results.
 A proof of concept for sustained delivery peptides with PSi
was provided in this work. Further development is needed in
order to fully realize the potential of the delivery system. Indeed,
the work has since then been continued by studying the
formulations of peptides and PSi and by providing delivery
systems capable of sustaining the release of peptides for up to
four days [127, 136].
Despite the vast interest in mesoporous drug delivery
systems, commercial products have not reached the markets so
far. It seems very likely that such products will emerge as the
current academic knowledge is now being utilized in
commercial developments by several companies such as Formac
Pharmaceuticals and pSivida.
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Joakim Riikonen
Modification, Characterization
and Applications of Mesoporous
Silicon-Based Drug Carriers
Mesoporous silicon and silica are 
materials consisting of small pores 
with diameters between 2 and 50 
nm. These materials exhibit high 
potential as drug carriers, since they 
are able to improve the delivery 
characteristics of drugs loaded 
inside the pores. The present thesis 
investigates the development of 
these materials for drug delivery 
applications. Modifications to 
the surface chemistry as well as 
modifications and characterization of 
the pore structure were studied. In 
addition, the physical state of drugs 
inside the pores was investigated. 
Finally, it was shown that porous 
silicon microparticles could be used 
to sustain the delivery of peptides in 
a biologically active form in vivo. 
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